lioton 1000iu/g gel
a. menarini industrie farmaceutiche riunite s.r.l., florencie array - 701 sodnÁ sŮl heparinu - gel - 1000iu/g - heparin
spasmomen 40mg potahovaná tableta
a. menarini industrie farmaceutiche riunite s.r.l., florencie array - 8340 otilonium-bromid - potahovaná tableta - 40mg - otilonium-bromid
quofenix
a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumin - získané infekce ve společenství - antibakteriální látky pro systémové použití, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 a 5. pozornost by měla být věnována oficiálním doporučením pro správné používání antibakteriálních látek.
glibomet 400mg/2,5mg potahovaná tableta
laboratori guidotti s.p.a., la vettola, (pisa) array - 2418 metformin-hydrochlorid; 1784 glibenklamid - potahovaná tableta - 400mg/2,5mg - metformin a sulfonylmoČoviny
nimesil 100mg granule pro perorální suspenzi
laboratori guidotti s.p.a., la vettola, (pisa) array - 8782 nimesulid - granule pro perorální suspenzi - 100mg - nimesulid
siofor 1000mg potahovaná tableta
laboratori guidotti s.p.a., la vettola, (pisa) array - 2418 metformin-hydrochlorid - potahovaná tableta - 1000mg - metformin
siofor 850mg potahovaná tableta
berlin-chemie ag, berlín array - 2418 metformin-hydrochlorid - potahovaná tableta - 850mg - metformin
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastická činidla - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
nexpovio
stemline therapeutics b.v. - selinexor - mnohočetný myelom - antineoplastická činidla - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
orserdu
stemline therapeutics b.v. - elacestrant - neoplasmy prsů - endokrinní terapie - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.